SHX Vaccines is taking a different approach to vaccinating against meningitis -- preventing meningococci from binding to host cells in the first place. The company's academic collaborators have proof of concept for the approach in human tissue explants, including efficacy against serotype B, the bacteria's most common but most intractable subgroup.